Experimental Therapeutics

实验治疗项目（ETP）的总体目标是建立一个世界级的学术中心，致力于在基础科学和转化科学之间建立桥梁，以设计创新和有效的癌症治疗方法。该项目最初名为分子治疗学项目，成立于2004年12月，汇集了来自15个不同部门的41名研究人员组成的跨学科小组。自上一个资助周期以来，实验治疗学项目的研究基础从7,878,482美元增加到16,042,852美元，年度直接研究支持总额增加了104%，其中3,683,482美元来自NCI。在上一个资助期内，实验治疗学项目成员共发表了539篇论文，其中9.3%是项目内的，21.1%是项目间的。由王绍萌博士和Judith Sebolt-Leopold博士领导。ETP专注于小分子靶向治疗的合理设计和开发，是基础科学和临床项目之间的关键纽带。ETP有四个主要的研究主题：

The overarching goal of the Experimental Therapeutics Program (ETP) is to build a world-class academic center dedicated to bridging basic and translational science for the design of Innovative and Impactful cancer therapies. This program, originally named the Molecular Therapeutics program, was established in December 2004 and brings together an interdisciplinary group of 41 investigators from 15 different departments. Since the last funding cycle the research base of the Experimental Therapeutics Program increased 104% from $7,878,482 to $16,042,852 total annual direct support with a total annual direct research support, of which $3,683,482 is from the NCI. Over the last grant period, there were a total of 539 publications of the Experimental Therapeutics Program members, of which 9.3% are intra-programmatic and 21.1% are inter-programmatic. Led by Shaomeng Wang, Ph.D. and Judith Sebolt-Leopold, Ph,D., the ETP has a strong focus on the rational design and development of small-molecule targeted therapies and serves as a critical link between the basic science and clinical programs. The ETP has four major research themes: I) Identification of novel therapeutic agents and approaches that target key signaling pathways dysregulated in human cancer, II) Improvement of drug delivery systems to address tumor inaccessibility using nanotechnology platforms, III) Execution of lead optimization and preclinical biomarker studies to guide development candidate selection and clinical trial design, IV) Translation of these new cancer medicines and approaches into the clinic.